Meta-analysis on the effects of octreotide on tumor mass in acromegaly
about
Recent advances in the management of acromegalyCurrent therapies and mortality in acromegalyPlace of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysisSafety of octreotide in hospitalized infants.Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.Pegvisomant in acromegaly: an update.Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guidelineExpert consensus document: A consensus on the medical treatment of acromegaly.Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot studyPasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression.Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.The role of primary pharmacological therapy in acromegaly.Multiple facets in the control of acromegaly.Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.Intraoperative magnetic resonance imaging during surgery for pituitary adenomas: pros and cons.Octreotide for acromegaly treatment: a reappraisal.HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies.New therapeutic agents for acromegaly.Management of aggressive growth hormone secreting pituitary adenomas.Current and future medical treatments for patients with acromegaly.The role of combination medical therapy in the treatment of acromegaly.Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.Surgical treatment and outcome of TSH-producing pituitary adenomas.Acromegalic osteopathy.Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.Recent Progress in the Medical Therapy of Pituitary TumorsCabergoline treatment in acromegaly: cons.HMGA2 cooperates with either p27(kip1) deficiency or Cdk4(R24C) mutation in pituitary tumorigenesis.A paradigm shift in the medical treatment of acromegaly: from a 'trial and error' to a personalized therapeutic decision-making process.Novel Somatostatin Receptor Ligands Therapies for Acromegaly.International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New NomenclatureUpdates in Diagnosis and Treatment of Acromegaly
P2860
Q26766199-C4351A60-84BA-427C-8E2C-673D8EA51DF9Q26776238-302D8D8B-D559-4B8F-BB00-6DBD12096226Q27693237-E2F55BD0-CD41-4178-8B4D-BC9D1F716F06Q33422773-0E07CB1A-B497-4093-848A-CBD32CA74108Q33564399-FC331183-9D34-4EDA-A623-0A8FD904B133Q33569037-E31CF08B-AD9F-44D2-89FB-C0C26A792A40Q33725999-C41BE0F7-C4DC-4C0A-AEF4-903D2DEAF707Q34277844-9D0E97AD-698D-4315-A412-60FC73F587A8Q34406566-677B2334-5DAD-4068-8BBF-1EAAF1704178Q36228181-BF895764-906E-4251-9279-82842E0EAC41Q36456312-79EE7A62-76E0-4139-99C4-CAB2370312DDQ36911589-C58B8DAB-AF1A-41C0-83A7-FEAF2978AE89Q36964536-E3687E20-2A4C-41ED-BBC6-7665D3EEF9F4Q37531005-2D485208-EC45-4706-A006-8DDA6AF7AC73Q37531066-745EC2D1-700B-476B-8876-C3DACD810525Q37617510-FC45B0A3-612F-4F76-8D61-68B36C5B2A73Q38029574-4B005850-8E6A-44CB-9323-0736AAC1F57BQ38152458-67732C00-3346-4620-8418-F62BEF43910FQ38397298-F0433C1E-450B-4F2E-BA86-5F50797AB576Q38648739-93EAE940-2CEC-44CD-9F7F-15951D5194C2Q38781620-B4C47B56-2533-4624-8EB5-3E9D13D9F335Q38847622-5C5CFBA5-460B-4267-BE1B-0DBEC89AEC2BQ38927318-C0A8BE7F-B5BE-43B2-B723-15A6DF435299Q38947158-D0ED7EE8-D4C7-44E4-878D-81D6158A6B9AQ38958674-216EACA6-3191-4E55-A1BE-C241FE35970BQ38973343-F2AF6ADC-28F2-4BE2-8F78-409B1EFFE9EFQ38990078-073D9D5C-798D-48BD-9D9D-45E3913F6BF3Q39420116-173B0928-FE5C-4027-A1B1-F388761F6BA3Q45844957-62A23B56-6E02-4735-8684-EE0FDAD43183Q47382950-DBE9A706-5D5F-4A56-91D7-AF0B3F850285Q50930330-0E201E22-1F4F-4CE3-ACDC-BA7CC05292ADQ52643700-1DA44924-8EB5-4FF0-B3BE-EC00CC364649Q57144951-9438F2EC-FC48-470E-9D39-36371843B523Q57822729-801FC5EB-9454-481A-ACA7-89C4A3C339FD
P2860
Meta-analysis on the effects of octreotide on tumor mass in acromegaly
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Meta-analysis on the effects of octreotide on tumor mass in acromegaly
@ast
Meta-analysis on the effects of octreotide on tumor mass in acromegaly
@en
Meta-analysis on the effects of octreotide on tumor mass in acromegaly
@nl
type
label
Meta-analysis on the effects of octreotide on tumor mass in acromegaly
@ast
Meta-analysis on the effects of octreotide on tumor mass in acromegaly
@en
Meta-analysis on the effects of octreotide on tumor mass in acromegaly
@nl
prefLabel
Meta-analysis on the effects of octreotide on tumor mass in acromegaly
@ast
Meta-analysis on the effects of octreotide on tumor mass in acromegaly
@en
Meta-analysis on the effects of octreotide on tumor mass in acromegaly
@nl
P2093
P2860
P1433
P1476
Meta-analysis on the effects of octreotide on tumor mass in acromegaly
@en
P2093
Andrea Giustina
Irene Floriani
Maurizio Spinello
Shlomo Melmed
Valter Torri
P2860
P304
P356
10.1371/JOURNAL.PONE.0036411
P407
P577
2012-05-04T00:00:00Z